Leonard Zehr, Author at BioTuesdays

Executive Moves

Theralase appoints internationally accomplished biopharma Executive, Dr. Kaouthar Lbiati, as independent board director

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) appointed Kaouthar Lbiati, M.D., as an independent director. Dr. Lbiati received a post-doctorate in clinical oncology from Gustave Roussy Institute in Paris, which is a...

June 6, 2023

Feature

Avivo developing universal donor blood type to expand transplants, safer transfusions

John Coleman, Ph.D., envisions a future where blood types cease to be a primary constraint in life-saving organ transplants and blood transfusions. “Recognizing the urgent need for solutions to these challenges, we have...

June 6, 2023

Markets

Research Capital likes Theralase data update; sees FDA breakthrough filing soon

Research Capital remains bullish on the ability of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), given the “strong data that has...

May 31, 2023

Markets

SVB ups Elevation Oncology to OP; PT to $8 on clinical update

SVB Securities upgraded Elevation Oncology (NASDAQ:ELEV) to “outperform” from “market perform” and raised its price target to $8 from $5, following the abstract release for EO-3021 (Claudin 18.2) ahead of ASCO. “This is...

May 30, 2023

Developments

GEN highlights iBio pivot to precision antibody immunotherapies

Genetic Engineering & Biotechnology News (GEN), in a feature article, outlines iBio’s (NYSE American:IBIO) transition from a contract development and manufacturing organization and cGMP biologics manufacturer to a...

May 30, 2023

Feature

Virax Biolabs readies clinical performance study of ViraxImmune Platform

Virax Biolabs (NASDAQ:VRAX) expects to begin in the third quarter a clinical performance study of its proprietary T-Cell testing platform, ViraxImmune, as a stepping stone for regulatory compliance in the U.S. and...

May 30, 2023

Feature

HDT Bio focused on global impact of mRNA vaccine platform

HDT Bio is developing messenger RNA vaccines addressing diverse indications in infectious diseases and oncology, and is utilizing regional partnerships for manufacturing, clinical development and commercialization.

May 23, 2023

Markets

Analysts give high marks to Hepion’s ATTITUDE NASH trial results

Analysts for Cantor Fitzgerald and Brookline Capital Markets gave high marks to Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2a ATTITUDE NASH trial results, which met its primary and secondary endpoints as well as showed...

May 22, 2023

Developments

Hepion Phase 2 ALTITUDE-NASH trial achieves all endpoints, improvement in liver function and NASH biomarkers

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive topline results from its recently completed Phase 2 ALTITUDE-NASH clinical trial with lead drug candidate, rencofilstat. ALTITUDE-NASH met its primary endpoint by...

May 22, 2023

Feature

ADvantage Therapeutics taking disruptive approach to mild Alzheimer’s

Closely-held ADvantage Therapeutics is awaiting regulatory approval in Europe to proceed with a Phase 2b confirmatory clinical trial of its lead drug candidate, AD04, for the treatment of mild Alzheimer’s disease (AD).

May 16, 2023

Author - Leonard Zehr

Theralase appoints internationally accomplished biopharma Executive, Dr. Kaouthar Lbiati, as independent board director

Avivo developing universal donor blood type to expand transplants, safer transfusions

Research Capital likes Theralase data update; sees FDA breakthrough filing soon

SVB ups Elevation Oncology to OP; PT to $8 on clinical update

GEN highlights iBio pivot to precision antibody immunotherapies

Virax Biolabs readies clinical performance study of ViraxImmune Platform

HDT Bio focused on global impact of mRNA vaccine platform

Analysts give high marks to Hepion’s ATTITUDE NASH trial results

Hepion Phase 2 ALTITUDE-NASH trial achieves all endpoints, improvement in liver function and NASH biomarkers

ADvantage Therapeutics taking disruptive approach to mild Alzheimer’s

General

More